Cellectricon signs collaboration agreement with AstraZeneca

05-May-2006

Cellectricon announced a collaboration with AstraZeneca, under which the companies will study the possibility of developing a new cell-based microfluidic screening platform. The collaboration aims to advance the performance of cell-based ion channel assays in screening applications.

"We are pleased that AstraZeneca sees the value of our microfluidic-based solutions for drug discovery", says Dr. Mattias Karlsson, VP Research & Development at Cellectricon. "The fantastic market acceptance of Dynaflow, our first generation of microfluidic-based tools supports the unique possibilities the micro-scale format offers such as superior performance characteristics and robustness."

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance